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116ERotaviruses (RVs) cause severe gastroenteritis in infants and young children; yet, several strains have been
isolated from newborns showing no signs of clinical illness. Two of these neonatal strains, RV3 (G3P[6]) and
116E (G9P[11]), are currently being developed as live-attenuated vaccines. In this study, we sequenced the
eleven-segmented double-stranded RNA genomes of cell culture-adapted RV3 and 116E and compared their
genes and protein products to those of other RVs. Using amino acid alignments and structural predictions, we
identiﬁed residues of RV3 or 116E that may contribute to attenuation or inﬂuence vaccine efﬁcacy. We also
discovered residues of the VP4 attachment protein that correlate with the capacity of some P[6] strains,
including RV3, to infect newborns versus older infants. The results of this study enhance our understanding
of the molecular determinants of RV3 and 116E attenuation and are expected to aid in the ongoing
development of these vaccine candidates.1, Bethesda, MD 20892-8026,
Donald).
Inc.Published by Elsevier Inc.Introduction
GroupA rotaviruses (RVs) are important pathogens that cause acute,
dehydratinggastroenteritis in infants and young children. The burdenof
disease is severe, particularly in developing countries where RV
infections lead to more than 500,000 deaths annually (Parashar et al.,
2006). RVs are non-enveloped, triple-layered icosahedral particles that
enclose an eleven-segmented, double-stranded (ds) RNA genome
(Pesavento et al., 2006). Together, the genome codes for six structural
proteins (VP1–VP4, VP6, and VP7) and ﬁve or six non-structural
proteins (NSP1–NSP5, and sometimes NSP6) (Estes and Kapikian,
2007). Individual RV strains have traditionally been classiﬁed into
serotypes based on the antibody responses generated against the
outermost structural proteins VP7 (G-serotypes) and VP4 (P-serotypes)
(Estes and Kapikian, 2007). Due to the ease of sequencing, RVs are now
classiﬁed into G/P-genotypes based on the relatedness of the genes
encoding VP7 and VP4 (Estes and Kapikian, 2007; Matthijnssens et al.,
2008a).Molecular sequencing of RVs has also led to the development of
a classiﬁcation system for the internal genes (i.e., dsRNA segments
encodingproteins other thanVP7 andVP4). In this system, each internal
gene is assigned a particular genotype based on established nucleotide
identity cut-off percentages (Matthijnssens et al., 2008a,b). Now, the
acronym Gx-P[x]-Ix-Rx-Cx-Mx-Ax-Nx-Tx-Ex-Hx is used to classify the
VP7–VP4–VP6–VP1–VP2–VP3–NSP1–NSP2–NSP3–NSP4–NSP5/6-encoding segments. The majority of human RVs sequenced to date
contain either genotype 1 (Wa-like) or genotype 2 (DS-1-like) internal
genes. However, reassortment events can lead to human strains
containing dsRNA segments with other genotypes.
Although the mechanism by which RV infection elicits immunolog-
ical protection is not fully understood, G/P-type-speciﬁc neutralizing
antibodies have been shown to play an important role (Ward, 2003).
Strains with G/P-type combinations of G1P[8], G2P[4], G3P[8], G4P[8],
and G9P[8] are the most prevalent causes of disease in humans
worldwide, and thus, are targets of the two currently licensed RV
vaccines (Santos and Hoshino, 2005). RotaTeq (Merck) contains ﬁve
live-attenuated, reassortant viruses with human VP7 (G1, G2, G3 and
G4) and VP4 (P[8]) genes in a predominantly bovine RV background
(strain WC3) (Matthijnssens et al., 2010a; Ciarlet and Schodel, 2009;
Heaton and Ciarlet, 2007). In contrast, Rotarix (GlaxoSmithKline) is a
live-attenuated, G1P[8] human RV (strain 89-12) containing genotype 1
internal genes (Ward, 2003). Both vaccines have proven safe and
effective at protecting against severe diarrheal disease in industrialized
countries and Latin America (Ruiz-Palacios et al., 2006; Vesikari et al.,
2006; Ward, 2003). However, the efﬁcacy of RotaTeq and Rotarix in
developing countries is expected to be reduced,whichmay be related to
viral serotype diversity among other factors (Madhi et al., 2010; Tate
et al., 2010). Additionally, the high monetary cost of these current
vaccines may limit their availability in regions of the world where they
aremost needed. As a result, there is a global health initiative to develop
new RV vaccines that can be manufactured on-site at a lower cost. Two
vaccine candidates being considered are the live-attenuated human
strains RV3 (G3P[6]) and 116E (G9P[11]).
Table 1
Sequence-based G-typing of RV3 and 116E VP7.
RV3 116EG-type Strain
%NTa %AAb %NT %AA
G1 Wa 75 83 75 79
G2 DS-1 73 75 74 76
G3 P 97 98 79 85
G4 ST3 74 76 75 78
G5 IAL28 77 86 78 81
G6 Se584 77 86 77 83
G8 69M 75 83 75 82
G9 Wi61 79 86 89 94
G10 A64 75 83 75 81
G12 L26 74 80 76 82
a Abbreviation: percent nucleotide identity (%NT).
b Abbreviation: percent amino acid identity (%AA).
Table 2
Sequence-based P-typing of RV3 and 116E VP4.
RV3 116EP-type Strain
%NTa %AAb %NT %AA
P[1] RF 69 73 60 59
P[2] SA11 71 74 59 58
P[4] DS-1 74 76 60 58
P[5] UK 66 68 59 58
P[6] ST3 98 96 59 56
P[8] Wa 74 77 59 58
P[9] AU-1 64 66 59 55
P[10] 69M 70 75 61 59
P[11] B223 58 56 91 94
a Abbreviation: percent nucleotide identity (%NT).
b Abbreviation: percent amino acid identity (%AA).
Table 3
Genotyping of RV3 and 116E internal genes.
RV3 v. Wa 116E v. WaGene %cut-offa
%NTb %AAc %NT %AA
VP1 83 96 98 96 99
VP2 84 94 97 94 98
VP3 81 98 99 89 92
VP6 85 90 98 91 98
NSP1 79 85 83 89 88
NSP2 85 91 95 92 96
NSP3 85 97 97 89 90
NSP4 85 98 96 96 97
NSP5 91 93 93 95 96
a Percent nucleotide identity cut-off values for genotyping.
b Abbreviation: percent nucleotide identity (%NT).
c Abbreviation: percent amino acid identity (%AA).
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(b28 days old) in hospital neonatal units in Australia (1977) and
India (1985), respectively (Albert et al., 1987; Glass et al., 2005).
Follow-up studies showed that the RV3- or 116E-infected newborns
did not experience episodes of severe diarrhea later in life when
compared with uninfected individuals (Bhan et al., 1993; Bishop et al.,
1983). This observation suggested that these attenuated strains might
protect against subsequent, symptomatic RV infection, providing
rationale for their development as vaccines. Clinical testing with cell
culture-adapted RV3 and 116E demonstrates that they are safe,
attenuated, and immunogenic in all age groups, and that they
replicate well in the infant gut (Barnes et al., 1997, 2002; Bhandari
et al., 2006, 2009). Moreover, phase II trials show that RV3 partially
protected infants against severe diarrhea during successive winter
months (Barnes et al., 2002). Studies are ongoing to determine
whether RV3 and 116E elicit broadly-protective immune responses
against heterotypic strains, or whether they will be limited to
preventing infections with G/P-type-matched strains. Because they
are being considered as vaccines, there is also great interest in
elucidating the molecular basis for the attenuated, neonatal pheno-
types of RV3 and 116E. Towards this goal, a few dsRNA segments have
been sequenced and analyzed for these viruses (Cunliffe et al., 1997;
Das et al., 1993; Gentsch et al., 1993; Kirkwood et al., 1996; Palombo
and Bishop, 1994b). Nonetheless, in the absence of complete RV3 and
116E genome sequences, it is impossible to fully identify attenuation
and neonatal infection determinants.
In this study, we deduced the nucleotide sequences of the open-
reading frames (ORFs) for each of the eleven dsRNA genome segments
of cell culture-adapted RV3 and 116E viruses. The segments were
classiﬁed into genotypes according to the nucleotide identity cut-off
percentages established by the Rotavirus Classiﬁcation Working
Group (RCWG). The genetic relatedness of RV3 and 116E genome
segments to those of other human and animal RVs was determined
using phylogenetic analyses. By performing amino acid alignments of
the deduced proteins, we identiﬁed residues of RV3 or 116E that may
contribute to their attenuation. Additionally, the three-dimensional
locations of VP7 residues speciﬁc to RV3 or 116E in comparison to
serotype-matched strains were mapped onto a high-resolution
structure of the glycoprotein trimer. This analysis revealed changes
that could inﬂuence the efﬁcacy of RV3 or 116E as vaccines. Equally
important, using amino acid alignments we found that the VP4
attachment proteins of P[6] strains isolated from neonates, such as
RV3, differed at several positions compared with P[6] RVs isolated
from older infants. While these changes do not correlate with diseaseFig. 1. Phylogenetic relationships of RV3 and 116E genome segments to those of other RVs. The
each isolate and are out-group rooted to DS-1 for purposes of clarity. Horizontal branch lengths
percentages for key nodes. Strain names are colored accordingly: animal strains (green), hum
Strains RV3 and 116E are highlighted in yellow.outcome, several of them localize to the protein surface and may
inﬂuence viral entry into cells of the neonatal gut. Together, the
results presented in this study are important for the continued
development of RV3- and 116E-based vaccines.Results
Genotype classiﬁcation of RV3 and 116E genes
The ORF nucleotide sequences for the eleven genome segments of
cell culture-adapted RV3 and 116E strains were determined. The
sequences deduced in this study are either identical or show a few
changes from those that are already in GenBank for RV3 (VP4, VP6,
and NSP4 genes) and 116E (VP4, VP6, VP7, NSP1, and NSP4 genes)
(Table S1) (Cunliffe et al., 1997; Das et al., 1993; Gentsch et al., 1993;
Kirkwood et al., 1996; Palombo and Bishop, 1994b). Genotypes were
assigned for each genome segment based on the nucleotide percent
identity cut-off values deﬁned by the RCWG and by submission to
RotaC (http://rotac.regatools.be) (Matthijnssens et al., 2008a,b; Maes
et al., 2009).
Our analyses show that RV3 can be classiﬁed as a G3P[6] strain,
which is consistent with previous reports (Albert et al., 1987;
Kirkwood et al., 1996). Speciﬁcally, RV3 VP7 shares 97% nucleotide
identity with the G3 human strain P (98% amino acid identity), and
RV3 VP4 shares 98% nucleotide identity with the P[6] human strain
ST3 (96% amino acid identity) (Tables 1 and 2). Also, like previous
reports, our results show that 116E is a G9P[11] strain, with a VP4 thatneighbor-joining treeswere constructed using the individual ORF nucleotide sequences for
are drawn to scale (nucleotide substitutions per base), and bootstrap values are shown as
an neonatal strains (red), and human strains isolated from older infants/children (black).
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Gentsch et al., 1993). In particular, 116E VP7 shares 89% nucleotide
identity with the G9 human strain Wi61 (94% amino acid identity),
while 116E VP4 shares 91% nucleotide identity with the P[11] bovine
strain B223 (94% amino acid identity) (Tables 1 and 2). Moreover, we
found that the nine internal genes of RV3 and 116E show percent
nucleotide identity values above the cut-offs when comparedwith the
genotype 1 prototype strain Wa (Table 3). Thus, RV3 and 116E have
genome constellations of G3-P[6]-I1-R1-C1-M1-A1-N1-T1-E1-H1 and
G9-P[11]-I1-R1-C1-M1-A1-N1-T1-E1-H1, respectively.
Phylogenetic relationship of RV3 and 116E to other strains
To further investigate the genetic relatedness of RV3 and 116E VP7
and VP4 genes with those of other G/P-type-matched strains, we
constructed phylogenetic trees using the ORF sequences and the
neighbor-joining method (Figs. 1A and B). Strain DS-1 (G2P[4]) was
included as an out-group in the analyses. The results show that RV3
VP7 clustered tightly with human G3 VP7s and away from those of
animal G3 strains (Fig. 1A). The VP7s of G9 strains have been
previously deﬁned into at least three phylogenetic lineages (1, 2, and
3) (Cao et al., 2008; Martinez-Laso et al., 2010). We found that 116E
VP7, which is the only representative of lineage 2, clustered with
lineage 1 VP7s and was distinct from lineage 3 VP7s (Fig. 1A). For VP4,
we found that RV3 segregated with other human P[6] strains and
away from the porcine P[6] strain Gottfried (Fig. 1B). Yet, interest-
ingly, RV3 VP4 was part of a subcluster of P[6] VP4s belonging to
human strains that were isolated from newborns (Fig. 1B). This
neonatal P[6] VP4 lineagewas separate from human RVs isolated from
infants or children (N28 days old) and contained both symptomatic
(strain 12/85) and asymptomatic (strains M37, 1076, NnB1, and ST3)
P[6] strains (Fig. 1B). As reported previously, 116E VP4 showed a close
phylogenetic relationship to VP4s of the human neonatal strains I321
(asymptomatic) and N155 (symptomatic), as well as to the P[11] VP4
proteins of several bovine RVs (Fig. 1B) (Gentsch et al., 1993; Glass
et al., 2005). This result is consistent with the notion that 116E, I321,
and N155 contain bovine RV VP4 genes.
We next sought to determine the phylogenetic relationships of the
RV3 and 116E genotype 1 internal genes to those of other RVs.
Although genotype 1 genes are predominantly found in human RVs
that cause disease in young children (i.e., human Wa-like strains),
several porcine and two bovine strains also contain dsRNA segments
classiﬁed as genotype 1 (Matthijnssens et al., 2008a). These porcine
RV-like genotype 1 genes generally cluster distantly from the human
RV genotype 1 genes in phylogenetic trees, suggesting that they
comprise distinct evolutionary lineages (Matthijnssens et al., 2008a).
For VP6, the porcine RV lineage was separate enough to warrant its
assignment as a different genotype I5 (Matthijnssens et al., 2008a,b).
In this study, we created neighbor-joining phylogenetic trees using
the internal gene ORF sequences of human, porcine, and bovine RVs
whose genomes contain several genotype 1 genes (Figs 1C–K). Fig. 2
summarizes the genome constellations of the viruses analyzed. Strain
DS-1 (genotype 2) was included in the trees as an out-group.
These results show that most of the RV3 and 116E internal genes
are quite similar to those of prototypic humanWa-like strains and are
more distantly related to porcine RV-like genes. Interestingly, seven of
the nine RV3 internal genes (VP1, VP2, VP6, NSP1, NSP3, NSP4, and
NSP5/6) clustered tightly with those of ST3, a G4P[6] strain that was
also isolated from an asymptomatic neonate (England, 1975)
(Chrystie et al., 1975; Wyatt et al., 1983) (Figs. 1C–E,G,I and J). RV3
VP3 and NSP2 genes did not cluster with ST3, but did show close
relationships to genes of other human strains (Figs. 1F,H, and K). The
116E VP1, VP2, VP6, and NSP1–5/6 genes segregated phylogenetically
with those of prototypic human Wa-like RVs and away from porcine
RV-like genes (Figs. 1C–E,G–K). However, 116E NSP4 formed a
separate branch, located just off the main group of human RV genes(Fig. 1J). Most strikingly, 116E VP3 did not group with any other
known human or animal genotype 1 genes (Fig. 1F). Using BLAST, we
found that the VP3 gene of 116E is most closely related that of strain
Wa; yet, these genes only share 89% nucleotide identity (Table 3).
While it is not possible to determine the ancestral origin of 116E VP3,
the branching pattern is consistent with a reassortment event. A
similar pattern was seen with several genes from the G11 human
strains Matlab36-02, KTM368, and Dhaka6 (Matthijnssens et al.,
2010b). Together, these phylogenetic analyses indicate that all of the
RV3 genome segments are most likely of human Wa-like RV origin.
These results also suggests that 116Emay be amulti-gene reassortant,
containing a bovine RV VP4 gene and a VP3 gene of unknown ancestry
in a human Wa-like RV background.Atypical residues of RV3 and 116E proteins
To gain insight into possible attenuation determinants for RV3 and
116E, we created alignments using the deduced amino acid
sequences. We found that RV3 proteins exhibit several amino acid
changes not yet documented in RVs whose sequences are available in
GenBank (Table 4). Speciﬁcally, each internal gene protein had one to
three amino acid differences when compared with other known RV
strains; many of these changes occurred at invariable sites in the
protein sequence (Table 4 and data not shown). Of particular interest
are the two amino acid changes (Y85C and G162V) in NSP4, a viral
non-structural protein that can function as an enterotoxin (Estes and
Kapikian, 2007). Though both changes are outside of the putative
toxin domain (NSP4 residues ∼114–135), the Y85C change is non-
conservative andmay inﬂuence the function of this protein (Estes and
Kapikian, 2007). Neither of these changes are seen in a RV3 NSP4
sequence determined from the primary stool specimen, indicating
that these have been acquired during cell culture passage (Kirkwood
et al., 1996) (Table S1). At 92 amino acids, the length of the putative
NSP6 protein of RV3 is identical to that of strain Wa, but contained
three changes compared with known strains (Table 4).
Consistent with the phylogenetic analysis using nucleotide
sequences, we found that RV3 VP7 is nearly identical at the amino
acid level to other human RV G3 VP7 proteins. We did discover two
residues of RV3 VP7 that are not seen in most other G3 proteins from
human RVs for which sequences are available in GenBank (Table 4 and
Fig. 3A). Speciﬁcally, RV3 VP7 has alanine and arginine at positions 97
and 280, respectively, while nearly every other human RV G3 VP7
protein shows serine and glutamine at these locations (Fig. 3A). By
mapping these residues onto the three-dimensional structure of the
VP7 trimer, we saw that the S97A change is located near antigenic
domain 7-1A (classic antigenic region A) (Fig. 3B) (Aoki et al., 2009;
Matthijnssens et al., 2010c). In contrast, the Q280R change is buried
underneath the VP7 trimer, likely at the VP6 interface (data not
shown). For RV3 VP4, all residues are represented in other human P[6]
RV strains (Table 4).
The amino acid alignments revealed that many of the 116E
proteins exhibit numerous residues not yet seen in other RVs whose
sequences are in GenBank (Table 5). Of the 116E internal gene
proteins, VP2, VP3, and NSP1 exhibit the largest number of changes
(4, 9, and 10 residues, respectively) (Table 5). The changes in NSP1 are
interesting in light of the attenuated phenotype of 116E, as this non-
structural protein can function as an interferon antagonist (Barro and
Patton, 2005). Moreover, VP1, VP6, NSP3, and NSP5 each show a single
residue differing for 116E compared with all other RV strains
(Table 5). The 116E NSP6 protein is predicted to be 92 amino acids
long, like that of RV3, and shows two changes compared with known
strains (Table 5). We found no amino acid residues that were unique
to 116E NSP2 and NSP4. The fact that 116E NSP4 did not show any
amino acids changes was surprising, given its distant phylogenetic
relationship to human RV genes at the nucleotide level.
Fig. 2. Genome constellations of several human and animal RVs. The schematic illustrates the genotype of each genome segment for several RV strains. The strain name is listed to the
left of the corresponding genome constellation, and the protein encoded by each gene is listed at the top. RV strain names are colored accordingly: animal strains (green), human
neonatal strains (red), and human strains isolated from older infants/children (black). Strains RV3 and 116E are highlighted in yellow. All genotype 1 genes are shown as white
boxes, non-genotype 1 genes are shown as grey boxes, and dotted boxes indicated genome segments in which no or only partial ORF sequences are available. Asterisks (*) indicate
sequences that were omitted from the phylogenetic trees for purposes of clarity.
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showed that its glycoprotein has several atypical residues. In
particular, we found 14 amino acids in 116E VP7 (positions 26, 41,
43, 57, 68, 87, 100, 133, 142, 145, 171, 179, 221, and 278) that differ
for the majority of G9 VP7s (Table 5). Most of these changes are
buried, but T87I, D100G, D145N, T171A, and S221N are located on the
surface of VP7 in proximity to potential sites of antibody binding
(Table 5 and Fig. 3C) (Aoki et al., 2009; Matthijnssens et al., 2010c).
Likewise, 116E VP4 contains 17 amino acid changes when compared
to other human and animal P[11] proteins (Table 5).P[6] VP4 residues that correlate with neonatal infection
Phylogenetic analysis at the nucleotide level suggested that the P[6]
VP4 genes of neonatal RVs, such as RV3, are genetically-divergent from
theP[6] VP4 geneof strains isolated from infants and children (N28 days
old). In agreement, using amino acid alignments, we discovered that the
P[6] VP4 proteins of neonatal RVs differed at several positions (73, 78,
167, 169, 217, 456, 539, 544, 553, 616, 646, and 695) compared with
those of non-neonatal strains (Fig. 4). While the correlation at each
positionwas not absolute, the observation that P[6] VP4 proteins of RVs
Table 4
Atypical residues of RV3 proteins.
Structural proteins Non-structural proteins
VP1 I732V NSP1 L138V
V741I C/Y/Q394W
VP2 S606G NSP2 A243V
M672T T244A
D/E256N
VP3 N139D
N686S NSP3 T137S
VP6 E/D86K NSP4 Y85C
G162V
VP7a,b S97A (7-1A, A)
Q280R NSP5 E46G
VP4c None NSP6 K27E
S30L
R63K
a Compared to human G3 RV sequences in GenBank.
b VP7 antigenic domain or region as deﬁned in Matthijnssens et al. (2010c) is
indicated in parentheses next to associated residue.
c Compared to P[6] RV sequences in GenBank.
Table 5
Atypical residues of 116E proteins.
Structural proteins Non-structural
proteins
VP1 G95V VP7a,b L26V NSP1 D94N
L41I N109T
VP2 Q/L123R I43V Q203R
Q180H L57V H237Y
E197D T87I (7-1A, A) Q/K292R
H850Y D100G (7-1A, A, B) K296E
L133F (B) H319R
VP3 D83N M142V I444V
N139K D145N (7-2, B) R451T
A184T T171A Y478S
A395T D179N
K/N480Q S221N (7-1B, B, C) NSP2 None
K496R A278T
K/T687I NSP3 S280A
K704E VP4c S73K
T807M N116S NSP4 None
T118V
VP6 A/V101S T136A NSP5 T/N113S
R138K
T148A NSP6 T49M
Y156F R56L
T181A
G221R
M226I
I241V
I241V
N326D
I402V
I651M
E675D
V698M
a Compared to human G9 RV sequences in GenBank.
b VP7 antigenic domain or region as deﬁned in Matthijnssens et al. (2010c) is
indicated in parentheses next to associated residue.
c Compared to P[11] RV sequences in GenBank.
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RVs was surprising. Importantly, because strains that cause symptom-
atic (strain 12/85) and asymptomatic (strains RV3, M37, 1076, NnB1,
and ST3) infections are conserved at these sites, we predict that they do
not contribute to virulence. Instead, we hypothesize that some or all of
these aminoacid changes confer P[6] strainswith the enhanced capacity
to infect newborns. By mapping these neonatal RV-speciﬁc VP4
differences onto the three-dimensional structure of the attachment
protein, we found that six of them (S73, S78, L167, H169, T199, and
V217) are located at the basal surface of VP8*, which is the trypsin-
activateddistal domainofVP4 (Fig. 5) (Dormitzer et al., 2004;Dormitzer
et al., 2002). It is possible that these residues allow P[6] RVs to adhere
more efﬁciently to cell surface receptors in the neonatal gut, thereby
aiding in viral entry.
Discussion
In many developing countries, RV infections are a leading cause of
illness and death among children less than 2 years of age (Parashar
et al., 2006). It is unclear whether the currently available RV vaccines
will be effective and affordable in these regions of the world (Tate
et al, 2010). Consequently, new vaccines are being generated, several
of which are based on live-attenuated strains isolated from newborn
infants. Two neonatal RV strains, RV3 and 116E, were adapted toFig. 3. Surface-exposed VP7 amino acids unique to RV3 or 116E. (A) Architecture of a RV virion s
changes in RV3 or 116E. In both images, a surface representation of the VP7 trimer crystal struc
been colored as follows: 7-1A (red), 7-1B (salmon), and 7-2 (purple). Amino acids unique to RV
labeled for a single monomer of the trimer.
Architecture of a RV virion modiﬁed with permission from B.V.V. Prasad.growth in culture by multiple passages in primary African green
monkey kidney (AGMK) cells (Palombo and Bishop, 1994b; Das et al.,
1993). Derivatives of these cell culture-adapted versions of RV3 and
116E have undergone several phases of clinical testing and were
proven safe and immunogenic (Barnes et al., 1997; Barnes et al., 2002;
Bhandari et al., 2006; Bhandari et al., 2009). Prior to this study, the
genome sequences of RV3 and 116E had not been determined, making
it difﬁcult to fully identify factors contributing to their inherent
attenuation. The results described in this report help close this gap in
knowledge by revealing amino acid atypical residues of proteins
encoded by these viruses. These changes are not only predicted to
inﬂuence virulence, but also impact neonatal host infection and thehowing the positions of VP7 and VP4. (B and C) Three-dimensional locations of amino acid
ture (PDB 3FMG) is shown. Residues comprising the putative neutralization domains have
3 or 116E, not represented in any other G-type-matched strains, are shown in cyan and are
209C.M. Rippinger et al. / Virology 405 (2010) 201–213efﬁcacy of RV3- or 116E-based vaccines. Still, it is important to note
that the RV3 and 116E strains sequenced in this study are not the
actual vaccine preparations. Also, the VP4, VP6, and NSP4 sequences of
the original RV3 stool isolate that are available in GenBank show
changes compared with the sequences we determined (Table S1)
(Palombo and Bishop, 1994b; Kirkwood et al., 1996). We think it is
possible that some of these changes resulted from adaptation to
growth in vitro. For 116E there is no available sequence information of
the original stool material. However, the 116E VP6, NSP1, and NSP4
sequences that we determined in this study exactly match those in
GenBank for the culture-adapted strain (Table S1) (Cunliffe et al.,
1997). For 116E VP7 and VP4, we found a few nucleotide and amino
acid changes compared to the sequences in GenBank (Das et al., 1993;
Gentsch et al., 1993) (Table S1). Because we passaged 116E six
additional times in AGMK cells (see Material and methods), it is
possible that these differences could be attributed to evolution of the
virus in culture. Themanufacturers have not released the sequences of
the RV3 or 116E vaccine preparations; thus, this study is the ﬁrst to
describe the complete genetic characteristics of these important cell
culture-adapted strains.
Why are strains RV3 and 116E attenuated?
RV infections of newborns are uncommonly documented, but are
generally asymptomatic. Factors such as the prevalence of maternal
antibodies and immature gut physiology likely contribute to the lack
of diarrhea in neonates (Haffejee, 1991). However, some of the strains
isolated from newborns also seem attenuated in older infants and
children, demonstrating that they are phenotypically different from
pathogenic RVs. The complete genome sequence of only one
asymptomatic neonatal strain, ST3 (G4P[6]), has been reported to
date, but partial genome sequences exist for M37 (G1P[6]) and I321
(G10P[11]) (Dunn et al., 1994; Heiman et al., 2008; Kirkwood and
Palombo, 1997; Palombo and Bishop, 1994a; Rao et al., 1995). Strains
M37 and I321 were originally considered as vaccine candidates, along
with RV3 and 116E, prior to studies showing that they are poorly
immunogenic or do not protect against RV disease (Bhandari et al.,
2006; Perez-Schael et al., 1994; Vesikari et al., 1991). While the
evolutionary origin of M37 is unknown, I321 is thought to have
derived from an inter-species transmission of a bovine RV to a human,
providing a basis for its lack of virulence (Sukumaran et al., 1992). On
the contrary, the attenuating determinants of ST3, RV3, and 116E
seem subtler, as the vast majority of their genes are of human RV
origin.
The atypical G/P-type combinations seen in RV3 and 116E may
contribute, at least in part, to their attenuated phenotypes. Speciﬁ-
cally, RV3 is a G3P[6] strain and, although G3 strains readily circulate
in the human population, they are usually combined with P[8] VP4
proteins (Albert et al., 1987; Kirkwood et al., 1996). Human RVswith P
[6] speciﬁcity are more rare, but can be seen with multiple G-types
(Matthijnssens et al., 2009). Interestingly, many P[6] strains have
been isolated from neonates with both symptomatic and asymptom-
atic infections, but there does not seem to be a clear correlation with
residues of VP4 and clinical illness (Hoshino et al., 2003; Santos et al.,
1994). Two RV3 internal genes (encoding VP6 and NSP4) had been
sequenced previously, revealing that they are similar to commonWa-
like human strains (Kirkwood et al., 1996; Palombo and Bishop,
1994b). Our results extend these ﬁndings and show that all of the
internal RV3 genes are classiﬁed as genotype 1. Despite their
phylogenetic similarities to pathogenic RV isolates, we found unique
amino acid changes in every RV3 internal gene protein. We
hypothesize that some of these point mutations contribute to the
attenuation of this strain.
In contrast to RV3, which seems to have human RV-like VP7 and
VP4 proteins, 116E is a G9 strain with a P[11] VP4 that is very similar
to that of several bovine RVs (Das et al., 1994; Das et al., 1993;Gentsch et al., 1993). The only other known P[11] human strains
were also isolated from neonates, suggesting that, like P[6] RVs,
those with P[11]-speciﬁcity may have an enhanced capacity to
replicate in the newborn gut. Previous sequence and RNA hybrid-
ization studies showed that 116E contains Wa-like internal genes
(Cunliffe et al., 1997; Das et al., 1993). Our results are consistent with
these earlier ones, but also indicate that many of the internal genes/
proteins of 116E are unusual compared with other genotype 1
genes/proteins. Most notably, the gene of the 116E RNA capping
enzyme, VP3, is distantly related to human and animal RV genotype
1 genes at the nucleotide level and shows 9 amino acid changes not
represented in any known RV sequence. It is possible that 116E
picked up its VP3 gene by reassorting with an unidentiﬁed Wa-like
RV ancestor. The changes in the other 116E proteins (e.g., the VP2
inner capsid) might reﬂect co-evolution driven by the requirement
to maintain VP3 interactions during viral replication. Alternatively,
116E VP3 could have accumulated point mutations via genetic drift;
however, the pressures that would have selected for such changes in
this enzyme are not obvious. Based on the available data, we
speculate that the ancestor of 116E may have been a human G9P[8]
strain that acquired a bovine P[11] VP4 gene and a VP3 gene from an
unknown RV during separate reassortment events. Because VP3 has
been shown to be a virulence determinant, it is possible that this
gene alone is responsible for the attenuation of 116E (Hoshino et al.,
1995). However, we think it is more likely that the combination
of changes in the 116E genome is responsible for its avirulent
phenotype. Of particular interest are the amino acid changes at
highly conserved positions of the interferon-antagonist NSP1 protein
of 116E (Barro and Patton, 2005).Does VP4 confer some RVs an enhanced capacity to infect newborns?
A surprising result of this study was the apparent relationship
between VP4 sequence and neonatal infection. The phylogenetic
clustering pattern we found is in agreement with analysis done on the
VP8* gene region of neonatal P[6] strains isolated in Brazil
(Mascarenhas et al., 2007). Using amino acid alignments, we found
that the VP4 proteins of neonatal P[6] RVs tend to differ at several
positions compared with P[6] strains isolated from older infants or
children. However, the correlation was not absolute; there are
examples of P[6] strains isolated from children that show neonatal
RV-like amino acids and vice-versa. Because P[6] strains that cause
symptomatic (strain 12/85) and asymptomatic (strains RV3, M37,
1076, NnB1, and ST3) infections are conserved at these sites, they
probably do not contribute to virulence (Santos et al., 1994).
However, these amino acid changes may confer some P[6] strains
with the enhanced capacity to infect newborns. We found that six of
them (S73, S78, L167, H169, T199, and V217) are located at the basal
surface of the VP8* core, which is exposed upon trypsin cleavage of
the VP4 spike. The location of these changes outside putative
neutralization domains suggests that these do not merely allow P[6]
strains to evade maternal antibodies. Instead, we hypothesize that the
changes help these viruses adhere more efﬁciently to cell surface
receptors in the neonatal gut. Interestingly, P[11] strains (including
116E, I321, and N155) also show serines at positions 73 and 78. Thus,
these two sites might be of particular importance in determining
whether a RV can establish an infection in a newborn. Treatment of
RV3 (P[6]) or 116E (P[11]) with neuraminidase does not alter
infectivity in cell culture, suggesting attachment is sialic-acid
independent (Ciarlet et al., 2002). Likewise, the VP4 proteins of all
known P[6] and P[11] strains do not conserve the sialic-acid-binding
residues of strain RRV (Matthijnssens et al., 2010c). These observa-
tions indicate that the VP4 amino acid changes identiﬁed in this study
may confer binding to alternative carbohydrate molecules or to
proteins present on the surface of neonatal enterocytes.
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Fig. 5. Locationof surface-exposedP[6]VP8* residues that correlatewithneonatal infection. The left imageshowsa surface representationof theVP4 crystal structure (PDB1KQR).Awhitebox
deﬁnes theposition of VP8*. The right images show theVP8* core from twodifferent viewpoints (front or back). The front viewpoint is rotated 90° to the right comparedwith the image in the
white box. The back viewpoint is rotated 180° to the left comparedwith the front. Residues comprising the putative neutralization domains of VP8* have been colored as follows: pink (8-1),
salmon (8-2), purple (8-3) and green (8-4). Residues that correlate with the capacity of P[6] strains to infect neonates are shown in cyan.
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The most signiﬁcant question that remains regarding monovalent
vaccines, such as RV3 (G3P[6]) and 116E (G9P[11]), is whether they
will be effective at protecting against disease brought on by
heterologous serotype strains (G1, G2, G4, P[4], P[8], etc.). The clinical
efﬁcacy of RV3, even in communities where G1 and G2 strains
dominated, provides indirect evidence of cross-protection with this
vaccine candidate (Bishop et al., 1983). RV3 VP7 shows a single amino
acid difference (S97A) located near epitope 7-1A when compared
with common human G3 RVs; yet, we do not expect this conservative
change to dramatically inﬂuence neutralization. In contrast, the VP7
protein of 116E is quite divergent from most other human G9 VP7s
and contains numerous amino acid changes located on the protein
surface. Because of the number of changes, we think that 116E might
be less effective at producing antibodies capable of protecting against
circulating G9 strains. In support of this notion, guinea pig hyper-
immune serum raised against 116E VP7 failed to robustly neutralize
several human G9 RVs in plaque reduction assays (Cao et al., 2008). In
fact, G9 strains with VP7 proteins belonging to phylogenetic lineage 1
may be more suitable for vaccines, as they more broadly cross-
neutralize other G9 strains in vitro (Hoshino et al., 2004). However,
studies in animal models have shown that CD4 and CD8 T cell
responses can contribute to serotype-independent protection for RVs
(Ward, 2003). If this is the case, vaccines that are based on human
Wa-like strains, such as RV3 and 116E, may be quite successful. The
ﬁndings from this study are expected to aid future research into the
true protective efﬁcacy of RV3 and 116E.
Materials and methods
Viruses and RNA isolation
RV3 was ampliﬁed from the original stool specimen in primary
AGMK cells (30 passages) and was triple-plaque puriﬁed during
passages 19 to 23 (Palombo and Bishop, 1994b). The virus was then
grown in monkey kidney (MA104) cells for N15 passages. An aliquotFig. 4. Alignment of P[6] VP4 showing residues that correlate with neonatal infection. The
names are to the left of each sequence and are colored according to Fig. 1. Grey shading ind
isolated from neonates are labeled. Blue arrows show the region of VP4 comprising the VPof this cell culture-adapted RV3 strain was generously provided to us
by Carl Kirkwood (Melbourne Children's Research Institute). Our
laboratory further ampliﬁed the virus (one passage) in MA104 cells
and used the clariﬁed infected cell culture supernatant for RNA
extraction and sequencing.
116E was ampliﬁed from the original stool specimen in primary
AGMK cells (2 passages), grown in MA104 cells (8 passages), and
plaque puriﬁed twice in MA104 cells (Das et al., 1993). An aliquot of
this cell culture-adapted 116E strain was sent to Taka Hoshino
(National Institutes of Health) from Jon Gentsch (Centers for Disease
Control). In the Hoshino laboratory, the virus was passaged six times
in primary AGMK cells, and an aliquot of the cell culture supernatant
was given to our laboratory for RNA extraction and sequencing.
For both viruses, RNAwas extracted from the clariﬁed supernatant
using TRIzol-LS as described by the manufacturer's protocol (Invitro-
gen). RNA was denatured in 50% dimethyl sulfoxide for 10 min at
94 °C and then used as template for RT-PCR.
RT-PCR and sequencing
Denatured RNA was used as template for RT-PCR to amplify cDNA
fragments corresponding to regions of RV3 or 116E gene ORFs. For
116E genome segments 1, 2, and 3, SuperScript II RT and Accuprime
Pfx Supermix were used according to the manufacturer's protocols
(both Invitrogen). For 116E segments 4, 5, 6, 7, 8, 9, 10 and 11 and all
eleven RV3 segments, the SuperScript One-Step system (Invitrogen)
was used according to the manufacturer's protocol. Primers are listed
in the Supplementary data (Table S2).
The RT-PCR reactions were electrophoresed in a 1% agarose gel, and
speciﬁc cDNA products were excised and puriﬁed using a QIAquick gel
extraction kit (Qiagen). The puriﬁed cDNAs were then sequenced with
an ABI Prism BigDye v3.1 terminator cycle sequencing kit (Applied
Biosystems Group). The dye terminator was removed using Performa
DTR (Edge Biosystems) and sequences were obtained with a 3730 DNA
Analyzer (Applied Biosystems). The sequence ﬁles were assembled and
veriﬁed using Sequencher 4.7 (Gene Codes Corporation). Nucleotide
sequences generated in this study have been deposited into GenBankVP4 amino acid sequences of several representative P[6] strains are shown. The strain
icates conservation of amino acid identity. Residues associated with most P[6] strains
8* core.
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FJ361201–FJ361211 (116E). Previously determined sequences for these
two strains have the following GenBank accession numbers: U16299
(RV3 VP4); U04741 (RV3 VP6); U42628 (RV3 NSP4); L14072 (116E
VP7); L07934 (116E VP4); U85998 (116E VP6); U85999 (116E NSP1);
and U78558 (116E NSP4).
Phylogenetic analyses, amino acid alignments, and structure-based
predictions
Phylogenetic trees were generated in MacVector 8.1.2 (Accelrys)
using the neighbor-joining method (1000 bootstrap repetitions) and
the Kimura-2 correction parameter. Amino acid alignments were
constructed with MacVector 8.1.2. using ClustalW, BLOSUM Series,
with the defaults set (open gap penalty of 10.0, extended gap penalty of
0.05, and delay divergence of 40%). Structural analysis of VP7 (PBD
3FMG), VP8* (PDB 1KQR), and VP5* (PDB 2B4H) was performed using
UCSF Chimera-Molecular Modeling System (Petterson et al., 2004).
GenBank accession numbers for all RV sequences used in this study are
included in the Supplemental data (Table S3).
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